An Evaluation of Neoadjuvant Chemoradiotherapy for Patients With Resectable Pancreatic Ductal Adenocarcinoma

HPB Surgery - United States
doi 10.1155/2013/298726
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: What Is the Best Protocol?

Annals of Gastroenterological Surgery
2020English

Increased Neutrophil-To-Lymphocyte Ratio After Neoadjuvant Therapy Is Associated With Worse Survival After Resection of Borderline Resectable Pancreatic Ductal Adenocarcinoma

Surgery
Surgery
2016English

A Systematic Review of Neoadjuvant Therapy Compared to the “Resection First” Approach for Patients With Borderline Resectable Pancreatic Adenocarcinoma

Journal of Cancer Therapy
2014English

Significance of Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Head Cancer: Pathological Local Invasion and Microvessel Invasion Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2019English

Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2018English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Journal of Carcinogenesis & Mutagenesis
2013English

Resectable Pancreatic Ductal Adenocarcinoma: Association Between Preoperative CT Texture Features and Metastatic Nodal Involvement

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2020English

A Pilot Trial of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Journal of Pancreatic Cancer
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy